biperiden has been researched along with Parkinsonian Disorders in 13 studies
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone." | 5.34 | Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. ( Cansel, N; Herken, H; Ozen, ME; Savas, HA; Yumru, M, 2007) |
| "DYT16 is an autosomal recessive dystonia-parkinsonism due to putative mutations at PRKRA gene." | 1.38 | DYT16: the original cases. ( Camargos, S; Cardoso, F; Lees, AJ; Singleton, A, 2012) |
| "When biperiden was combined with SKF-82958, contraversive circling also was enhanced and ipsiversive circling decreased." | 1.35 | Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions. ( Domino, EF; Ni, L, 2008) |
| "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone." | 1.34 | Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. ( Cansel, N; Herken, H; Ozen, ME; Savas, HA; Yumru, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (61.54) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domino, EF | 1 |
| Ni, L | 1 |
| Camargos, S | 1 |
| Lees, AJ | 1 |
| Singleton, A | 1 |
| Cardoso, F | 1 |
| TIMBERLAKE, WH | 1 |
| SCHWAB, RS | 1 |
| ENGLAND, AC | 1 |
| ROSEN, A | 1 |
| DI CRISTO, G | 1 |
| PIRO, S | 1 |
| SCARPELLINO, F | 1 |
| UMBACH, W | 1 |
| ALLEVA, PM | 1 |
| MISEVIC, G | 1 |
| JANEVICIUS, V | 1 |
| CSALANY, L | 1 |
| MILLER, V | 1 |
| O'DOHERTY, DS | 1 |
| EDWARDS, CE | 1 |
| Cosentino, C | 1 |
| Ozen, ME | 1 |
| Yumru, M | 1 |
| Savas, HA | 1 |
| Cansel, N | 1 |
| Herken, H | 1 |
| Klintenberg, R | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
13 other studies available for biperiden and Parkinsonian Disorders
| Article | Year |
|---|---|
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benza | 2008 |
DYT16: the original cases.
Topics: Adolescent; Adult; Age of Onset; Anti-Dyskinesia Agents; Antiparkinson Agents; Baclofen; Biperiden; | 2012 |
Biperiden (Akineton) in Parkinsonism.
Topics: Biperiden; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders | 1961 |
[Drug-induced parkinsonism and its treatment with Akineton].
Topics: Biperiden; Humans; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders; Tranquilizing Agen | 1963 |
[Akineton in neurologic therapy with special reference to various forms of parkinsonism].
Topics: Biperiden; Humans; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders | 1963 |
[CLINICAL EXPERIENCES WITH DEPOT FORMS OF ANTI-PARKINSON DRUGS (AKINETON AND KR 339 KNOLL)].
Topics: Antiparkinson Agents; Biperiden; Bridged-Ring Compounds; Parasympatholytics; Parkinsonian Disorders | 1963 |
[AKINETON IN PARKINSONISM CAUSED BY DRUGS].
Topics: Anti-Allergic Agents; Biperiden; Haloperidol; Histamine H1 Antagonists; Movement Disorders; Neurolog | 1963 |
THE USE OF AKINETON FOR PARKINSONISM.
Topics: Biperiden; Parasympatholytics; Parkinsonian Disorders | 1964 |
THE EFFECTS OF BIPERIDEN HYDROCHLORIDE (AKINETON) IN POST-ENCEPHALITIC PARKINSONISM.
Topics: Biomedical Research; Biperiden; Drug Therapy; Encephalitis; Parasympatholytics; Parkinson Disease, P | 1964 |
Akineton in the treatment of parkinsonism.
Topics: Biperiden; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders | 1960 |
Ecstasy and acute dystonia.
Topics: Acute Disease; Adolescent; Adrenergic Uptake Inhibitors; Biperiden; Dose-Response Relationship, Drug | 2004 |
Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
Topics: Adult; Antipsychotic Agents; Biperiden; Diagnosis, Differential; Diazepam; Drug Therapy, Combination | 2007 |
Tardive dyskinesia model in the common marmoset.
Topics: Animals; Biperiden; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2002 |